AND ANSWERS WITH SOLUTIONS 2024
HowUoftenUdoesUtheUCDCUpublishUnewUimmunizationUschedules?
A.UThreeUtimesUperUyear
B.UAfterUeachUACIPUmeeting
C.UAnnually
D.UEveryUtwoUyearsU-UANSWERUC.UAnnually
WhichUofUtheUfollowingUstatementsUisUtrueUaboutUrisksUassociatedUwithUvaccinesUandUvaccine-
preventableUdiseases?
A.UAvailableUdataUindicateUthatUthimerosalUinUvaccinesUcausesUautism
B.UVaccinesUhaveUbeenUassociatedUwithUtheUdevelopmentUofUautoimmuneUdisordersUsuchUasUmultipleUscl
erosisU
C.UGivingUseveralUvaccinesUonUtheUsameUdayUoverloadsUtheUpatient'sUimmuneUsystem
D.UInternationalUtravelersUimportUmanyUcasesUofUvaccine-
preventableUdiseasesUintoUtheUUnitedUStatesUeachUyearU-
UANSWERUD.UInternationalUtravelersUimportUmanyUcasesUofUvaccine-
preventableUdiseasesUintoUtheUUnitedUStatesUeachUyear
HowUshouldUTdapUbeUadministeredUtoUpregnantUwomen?
A.UAdministerUoneUdoseUeitherUpriorUtoUpregnancyUorUimmediatelyUpost-partum
B.UAdministerUoneUdoseUwithUeveryUpregnancy,UupUtoUaUmaximumUofU3Udoses
C.UAdministerUoneUdoseUwithUeachUpregnancyUinUtheUthirdUtrimester
D.UAdministerUoneUdoseUonlyUifUtheUwomanUisUpregnantUinUtheUfallUseasonU-
UANSWERUC.UAdministerUoneUdoseUwithUeachUpregnancyUinUtheUthirdUtrimester
WhichUofUtheUfollowingUvaccinesUshouldUbeUadministeredUtoUboysUandUyoungUmenUagedU9UthroughU26Uye
arsUtoUreduceUtheirUlikelihoodUofUacquiringUgenitalUwarts?
, A.UHPV
B.UHib
C.UVaricella
D.UMenBU-UANSWERUA.UHPV
Michael,UaU47-year-
oldUhealthUcareUworker,UhasUnoUlaboratoryUevidenceUofUimmunityUtoUmeaslesUorUmumpsUandUcannotUconf
irmUthatUheUhadUeitherUdisease.UHowUmanyUdosesUofUMMRUvaccineUshouldUMichaelUreceive?
A.UOneUdoseUofUMMR
B.UTwoUdosesUofUMMR
C.UNoUdosesUofUMMRUbecauseUheUisUconsideredUimmuneUtoUmeaslesUandUmumps
D.UNoUdosesUofUMMRUbecauseUheUcouldUpassUtheUvirusUtoUhisUpatientsUafterUreceivingUtheUvaccineU-
UANSWERUB.UTwoUdosesUofUMMR
TashaUisUaU26-year-
oldUwomanUwithUrheumatoidUarthritisUwhoUisUtreatedUwithUimmunosuppressiveUtherapy.UWhichUofUtheUfo
llowingUvaccinesUshouldUbeUavoidedUforUTasha?
A.UHPV
B.UMenACWY
C.UMMR
D.UHerpesUZosterU(RZV)U-UANSWERUC.UMMR
IfUaUpatientUisUexperiencingUanaphylaxisUandUrequiresUepinephrine,UwhatUisUtheUdoseUandUrouteUofUadmini
strationUusingUaU1:1000U(1mg/mL)Uproduct?
A.U1Umg/kgUIMUinUtheUdeltoidUmuscle
B.U0.5mgUIIMUinUtheUdeltoidUmuscle
C.U1UmgUIMUinUtheUanterolateralUaspectUofUtheUthigh